RFK Jr.'s hand-picked committee approves manufacture of peptides he uses
There's no human safety or efficacy data, but that no longer seems to matter.
The FDA committee vote reads less like a scientific milestone and more like a scheduled outcome. Robert F. Kennedy Jr. did not merely arrive at a neutral panel; he curated its membership, telegraphed the direction months in advance, and then watched it deliver. That sequence is the story.
The mechanics are straightforward. Peptides are short chains of amino acids, some of which, like insulin, have well-understood receptor activity. Others do not. The committee endorsed lifting manufacturing restrictions on four of them, with three more queued for the following day. The unifying feature of the batch is not demonstrated safety or efficacy. It is the Secretary's personal enthusiasm.
The structural concern is the inversion of evidentiary logic. Standard pharmaceutical approval assumes that restrictions loosen as data accumulates. Here, restrictions loosen first, and the data question is left open. Manufacturers gain latitude to compound and sell these substances for human use while the evidence base remains thin. The market signal is clear: production capacity will expand before clinical justification catches up.
The political leverage is equally visible. A hand-picked committee produces a favorable vote, which the agency can then cite as expert consensus. The Secretary's prior advocacy becomes, through procedural alchemy, the considered judgment of an independent body. It is a familiar pattern in regulatory capture, executed with unusual transparency.
For the peptide industry, the practical effect is a near-term expansion of the addressable market. For consumers, it is the introduction of injectable compounds into wellness and longevity channels without the usual evidentiary guardrails. The committee's divided vote suggests the panel itself recognized the trade-off; the outcome suggests the trade-off was acceptable to the people who mattered.
The deeper question is what this signals about the broader regulatory environment. When a senior official can pre-select advisors, preview the conclusion, and still secure a formal endorsement, the advisory process functions as confirmation rather than deliberation. The peptides are the specific case. The precedent is the general one.